touchEXPERT BRIEFING Advances in the treatment of lupus and Sjögren’s disease
Watch leading experts discuss updates in the treatment of systemic lupus erythematosus (SLE), lupus nephritis (LN) and Sjögren’s disease, based on data presented at EULAR 2024.
Diagnosing, monitoring & managing SLE
Dr Faria presents a short introduction to SLE and LN, and summarises the points discussed in the EULAR 2024 session: Lupus: What’s on the horizon?
view bio and disclosures 1/5 Next InterviewIn this interview, Dr Faria answers the following questions:
- Could you provide a brief overview of SLE, including its symptoms, clinical presentations and severity levels?
- What is known about the pathogenesis of SLE and LN?
- How are SLE and LN currently managed, and what are the key limitations of these treatments?
- How do biomarkers currently help with diagnosing and monitoring treatment of SLE and LN?
- Were there any advances and/or research discussed at EULAR in the area of biomarkers?
Dr Raquel Faria is Internal Medicine Consultant & Clinical Immunologist at the Clinical Immunology Unit, Santo António University Hospital Center, University of Porto, Porto, Portugal.
Dr Raquel Faria discloses:
Advisor for GSK and AstraZeneca.
Exploring CAR-T cell therapy in SLE
In this video, Dr Parodis explores the potential of CAR-T cell therapy in treating SLE and LN and explores how these treatments will potentially fit into the future treatment landscape.
view bio and disclosures 2/5 Next InterviewDr Ioannis Parodis answers the following questions:
- Why is CAR-T cell therapy considered a viable therapeutic option for SLE and LN?
- How do you see these treatments fitting into the current treatment landscape in future?
Dr Ioannis Parodis is Senior Rheumatology Consultant, at the Karolinska University Hospital and Associate Professor of Rheumatology at the Karolinska Institute, Stockholm, Sweden.
Dr Ioannis Parodis discloses:
Consultant for GSK, Amgen, Biogen, and Roche. Advisory board member for GSK, Novartis, AstraZeneca, Aurinia, and Otsuka. Grant/research from BMS, Roche, GSK, Otsuka, and Aurinia. Honoraria from GSK, AstraZeneca, and Roche.
Advancements in treating SLE and LN
Dr Parodis outlines recent advances in approved treatments of SLE and LN from EULAR 2024, and discusses their potential clinical impact.
view bio and disclosures 3/5 Next InterviewDr Ioannis Parodis answers the following questions:
- At EULAR 2024, what did we see in terms of advancements of already approved treatments for SLE and LN?
Dr Ioannis Parodis is Senior Rheumatology Consultant, at the Karolinska University Hospital and Associate Professor of Rheumatology at the Karolinska Institute, Stockholm, Sweden.
Dr Ioannis Parodis discloses:
Consultant for GSK, Amgen, Biogen, and Roche. Advisory board member for GSK, Novartis, AstraZeneca, Aurinia, and Otsuka. Grant/research from BMS, Roche, GSK, Otsuka, and Aurinia. Honoraria from GSK, AstraZeneca, and Roche.
Recognising Sjögren’s disease and its impact
In this video, Dr Yusof gives an overview of Sjögren’s disease and its impact on those living with the condition.
view bio and disclosures 4/5 Next InterviewIn this interview, Dr Yuzaiful Yusof answers the following questions:
- What is Sjögren’s disease?
- How does Sjögren’s disease impact the lives of those living with the condition?
- How is Sjögren’s disease often diagnosed, and what are the key challenges when it comes to recognising patients with the condition?
Dr Yuzaiful Yusof is Senior Research Fellow and Consultant Rheumatologist at the Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK.
Dr Yuzaiful Yusof discloses:
Consultant for Aurinia and UCB. Participating in a speakers bureau for Roche, Novartis, Alums and Virfor.
Assessing current & novel treatments in Sjögren’s disease
Dr Yusof outlines the pathology of Sjögren’s disease, as well as current and future treatments, and lessons learnt in measuring efficacy of treatment.
view bio and disclosures 5/5 Leave FeedbackIn this interview, Dr Yuzaiful Yusof answers the following questions:
- What is currently known about the pathophysiology of Sjögren’s disease?
- How is Sjögren’s disease currently treated and what are the limitations of current options?
- When considering novel treatments, how best can we assess treatment efficacy?
- What do we need to consider in terms of safety when considering these novel therapeutic options?
Dr Yuzaiful Yusof is Senior Research Fellow and Consultant Rheumatologist at the Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK.
Dr Yuzaiful Yusof discloses:
Consultant for Aurinia and UCB. Participating in a speakers bureau for Roche, Novartis, Alums and Virfor.
Overview & Learning Objectives
Overview
Watch three leading experts, Drs Faria, Parodis and Yusof, discuss updates in the treatment of systemic lupus erythematosus (SLE), lupus nephritis (LN) and Sjögren’s disease, based on data presented at EULAR 2024.
Learning Objectives
After watching this activity, participants should be better able to:
For systemic lupus erythematosus (SLE) and lupus nephritis (LN)
- Understand the symptoms and pathogenesis of SLE and LN
- Discuss current treatment strategies for lupus and their possible limitations
- Provide an overview of advances with existing treatments for lupus presented at EULAR 2024, including the potential use of CAR-T cell therapy
For Sjögren’s disease
- Appreciate the burden and pathology of Sjögren’s disease and the challenges of diagnosis
- Outline current treatments for Sjögren’s disease and their possible limitations
- Give an overview of novel treatments for Sjögren’s disease, including those presented at EULAR 2024
Faculty & Disclosures
Dr Raquel Faria
University of Porto, Porto, Portugal
Dr Raquel Faria is Internal Medicine Consultant & Clinical Immunologist at the Clinical Immunology Unit, Santo António University Hospital Center, University of Porto, Porto, Portugal.
Dr Raquel Faria discloses:
Advisor for GSK and AstraZeneca.
Dr Ioannis Parodis
Karolinska Institute, Stockholm, Sweden
Dr Ioannis Parodis is Senior Rheumatology Consultant, at the Karolinska University Hospital and Associate Professor of Rheumatology at the Karolinska Institute, Stockholm, Sweden.
Dr Ioannis Parodis discloses:
Consultant for GSK, Amgen, Biogen, and Roche. Advisory board member for GSK, Novartis, AstraZeneca, Aurinia, and Otsuka. Grant/research from BMS, Roche, GSK, Otsuka, and Aurinia. Honoraria from GSK, AstraZeneca, and Roche.
Dr Yuzaiful Yusof
Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK
Dr Yuzaiful Yusof is Senior Research Fellow and Consultant Rheumatologist at the Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK.
Dr Yuzaiful Yusof discloses:
Consultant for Aurinia and UCB. Participating in a speakers bureau for Roche, Novartis, Alums and Virfor.
